Literature DB >> 34427026

The sodium-glucose co-transporter 2 inhibitor dapagliflozin improves prognosis in systolic heart failure independent of the obesity paradox.

Salvatore Carbone1,2, Adrian daSilva-deAbreu3,4, Carl J Lavie5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34427026      PMCID： PMC8628197          DOI： 10.1002/ejhf.2336

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN： 1388-9842            Impact factor:   17.349


× No keyword cloud information.
  17 in total

1.  Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.

Authors:  John J V McMurray; Scott D Solomon; Silvio E Inzucchi; Lars Køber; Mikhail N Kosiborod; Felipe A Martinez; Piotr Ponikowski; Marc S Sabatine; Inder S Anand; Jan Bělohlávek; Michael Böhm; Chern-En Chiang; Vijay K Chopra; Rudolf A de Boer; Akshay S Desai; Mirta Diez; Jaroslaw Drozdz; Andrej Dukát; Junbo Ge; Jonathan G Howlett; Tzvetana Katova; Masafumi Kitakaze; Charlotta E A Ljungman; Béla Merkely; Jose C Nicolau; Eileen O'Meara; Mark C Petrie; Pham N Vinh; Morten Schou; Sergey Tereshchenko; Subodh Verma; Claes Held; David L DeMets; Kieran F Docherty; Pardeep S Jhund; Olof Bengtsson; Mikaela Sjöstrand; Anna-Maria Langkilde
Journal:  N Engl J Med       Date:  2019-09-19       Impact factor: 91.245

2.  Disparate effects of obesity on survival and hospitalizations in heart failure with preserved ejection fraction.

Authors:  Salvatore Carbone; Carl J Lavie
Journal:  Int J Obes (Lond)       Date:  2020-04-20       Impact factor: 5.095

3.  Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial.

Authors:  Milton Packer; Stefan D Anker; Javed Butler; Gerasimos Filippatos; Joao Pedro Ferreira; Stuart J Pocock; Naveed Sattar; Martina Brueckmann; Waheed Jamal; Daniel Cotton; Tomoko Iwata; Faiez Zannad
Journal:  J Am Coll Cardiol       Date:  2021-03-23       Impact factor: 24.094

4.  Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics.

Authors:  Carlos G Santos-Gallego; Juan Antonio Requena-Ibanez; Rodolfo San Antonio; Kiyotake Ishikawa; Shin Watanabe; Belen Picatoste; Eduardo Flores; Alvaro Garcia-Ropero; Javier Sanz; Roger J Hajjar; Valentin Fuster; Juan J Badimon
Journal:  J Am Coll Cardiol       Date:  2019-04-23       Impact factor: 24.094

Review 5.  Meta-analysis of the relation of body mass index to all-cause and cardiovascular mortality and hospitalization in patients with chronic heart failure.

Authors:  Abhishek Sharma; Carl J Lavie; Jeffrey S Borer; Ajay Vallakati; Sunny Goel; Francisco Lopez-Jimenez; Armin Arbab-Zadeh; Debabrata Mukherjee; Jason M Lazar
Journal:  Am J Cardiol       Date:  2015-02-18       Impact factor: 2.778

6.  Effects of empagliflozin on cardiorespiratory fitness and significant interaction of loop diuretics.

Authors:  Salvatore Carbone; Justin M Canada; Hayley E Billingsley; Dinesh Kadariya; Dave L Dixon; Cory R Trankle; Leo F Buckley; Roshanak Markley; Chau Vo; Horacio Medina de Chazal; Sanah Christopher; Raffaella Buzzetti; Benjamin W Van Tassell; Antonio Abbate
Journal:  Diabetes Obes Metab       Date:  2018-04-23       Impact factor: 6.577

Review 7.  The role of diet and nutrition in heart failure: A state-of-the-art narrative review.

Authors:  Hayley E Billingsley; Scott L Hummel; Salvatore Carbone
Journal:  Prog Cardiovasc Dis       Date:  2020-08-14       Impact factor: 8.194

Review 8.  Differential Pathophysiological Mechanisms in Heart Failure With a Reduced or Preserved Ejection Fraction in Diabetes.

Authors:  Milton Packer
Journal:  JACC Heart Fail       Date:  2021-08       Impact factor: 12.035

9.  The effects of canagliflozin compared to sitagliptin on cardiorespiratory fitness in type 2 diabetes mellitus and heart failure with reduced ejection fraction: The CANA-HF study.

Authors:  Salvatore Carbone; Hayley E Billingsley; Justin M Canada; Edoardo Bressi; Brando Rotelli; Dinesh Kadariya; Dave L Dixon; Roshanak Markley; Cory R Trankle; Richard Cooke; Krishnasree Rao; Keyur B Shah; Horacio Medina de Chazal; Juan Guido Chiabrando; Alessandra Vecchié; Megan Dell; Virginia L Mihalick; Roberta Bogaev; Linda Hart; Benjamin W Van Tassell; Ross Arena; Francesco S Celi; Antonio Abbate
Journal:  Diabetes Metab Res Rev       Date:  2020-06-15       Impact factor: 4.876

10.  Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index.

Authors:  Carly Adamson; Pardeep S Jhund; Kieran F Docherty; Jan Bělohlávek; Chern-En Chiang; Mirta Diez; Jarosław Drożdż; Andrej Dukát; Jonathan Howlett; Charlotta E A Ljungman; Mark C Petrie; Morten Schou; Silvio E Inzucchi; Lars Køber; Mikhail N Kosiborod; Felipe A Martinez; Piotr Ponikowski; Marc S Sabatine; Scott D Solomon; Olof Bengtsson; Anna Maria Langkilde; Daniel Lindholm; Mikaela Sjöstrand; John J V McMurray
Journal:  Eur J Heart Fail       Date:  2021-07-29       Impact factor: 17.349
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.